FDA records list a supplemental approval dated 2 October 2026 for pirtobrutinib, a non-covalent (reversible) BTK inhibitor marketed in the US as Jaypirca, under application NDA 216059. The record does not state what the supplement changed, whether an indication, dosing information, or other labelling.
Supplements are often administrative or labelling updates rather than new indications. Prescribers using pirtobrutinib should check the current US label for any change. Its approval status in India through CDSCO is unknown.
- Check the current pirtobrutinib label for changes before prescribing.
- Do not assume a supplement means a new indication.
- Pirtobrutinib's approval status in India is unknown.
Why it matters
Label supplements can change dosing or interaction advice without a public announcement.
Don't overread it
A licence supplement is not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free